Hepatology International · 2022 · 32 citations · 25 references
MedicineOncologySurgeryGastrointestinal OncologyOncologic SurgerySurgical OncologyOncologic InterventionsRadiation TherapyHepatobiliary Cancer RadiotherapyHepatocellular Carcinoma RadiotherapyHepatocellular Carcinoma ResectionHepatocellular Carcinoma TreatmentLiver Tumor TherapyOptimal Treatment RegimesPrognostic Subgroup AnalysisPropensity Score Adjustment
BACKGROUND: The optimal locoregional treatment for hepatocellular carcinoma (HCC) patients with portal vein tumor thrombus (PVTT) is unclear. This study aimed to investigate the efficacy of Gamma knife radiosurgery (GKR) versus transcatheter arterial chemoembolization (TACE) in HCC patients with PVTT. METHODS: This retrospective study included 544 HCC patients with PVTT (GKR, 202; TACE, 342). Propensity score matching (PSM) analysis identified 171 matched pairs of patients. The primary endpoint was overall survival (OS). RESULTS: Before PSM, the GKR group exhibited longer median OS (mOS) than the TACE group (17.2 vs. 8.0 months, p < 0.001). We followed the Cheng's classification for PVTT. In the subgroup analysis, GKR was associated with significantly longer mOS for patients with PVTT II-IV (17.5 vs. 8.7 months, p < 0.001; 17.2 vs. 7.8 months, p = 0.001; 14.5 vs. 6.5 months, p = 0.001, respectively) and comparable OS for patients with PVTT I. After PSM, the GKR group had also a longer mOS than the TACE group (15.8 vs. 10.4 months, p < 0.001). In the subgroup analysis, the GKR group demonstrated superior mOS for patients with PVTT II-IV (all p < 0.05) and comparable OS for patients with PVTT I. CONCLUSIONS: GKR was associated better OS than TACE in HCC patients with PVTT, especially for patients with PVTT II-IV. CLINICAL TRIALS REGISTRATION: The study was registered in the Chinese Clinical Trials Registry under the registration number ChiCTR2100051057.
25
Management of Hepatocellular Carcinoma: An Update Δσ
Jordi Bruix, Morris Sherman · Hepatology · 2011 · 8.1K citations · Full text
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn, Shukui Qin, Masafumi Ikeda et al. · New England Journal of Medicine · 2020 · 7.2K citations · Full text
Medicine, Oncology, Pharmacotherapy +12
Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition)
Jian Zhou, Hui‐Chuan Sun, Zheng Wang et al. · Liver Cancer · 2020 · 833 citations · Full text